Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
International Society for Gastrointestinal Hereditary Tumours |
RCV000076261 | SCV000107282 | pathogenic | Lynch syndrome | 2013-09-05 | reviewed by expert panel | research | Coding sequence variation introducing premature termination codon |
Gene |
RCV000483706 | SCV000568631 | pathogenic | not provided | 2017-03-23 | criteria provided, single submitter | clinical testing | This variant is denoted MSH2 c.1738G>T at the cDNA level and p.Glu580Ter (E580X) at the protein level. The substitution creates a nonsense variant, which changes a Glutamic Acid to a premature stop codon (GAA>TAA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. MSH2 Glu580Ter has been found to be associated with reduced mRNA expression (Casey 2005). In addition, this variant has been observed in at least one individual with a malignant mixed glioma and several individuals with personal and/or family histories of colon cancer, some of which met Amsterdam or Bethesda Lynch Syndrome criteria and whose corresponding tumors were often microsatellite unstable and/or had abnormal protein staining on immunohistochemistry (Leung 1998, Chen 1999, Mangold 2005, Jasperson 2010, Brieger 2011). Based on currently available evidence, we consider this variant to be pathogenic. |
Ambry Genetics | RCV000491635 | SCV000580455 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-07-29 | criteria provided, single submitter | clinical testing | The p.E580* pathogenic mutation (also known as c.1738G>T), located in coding exon 11 of the MSH2 gene, results from a G to T substitution at nucleotide position 1738. This changes the amino acid from a glutamic acid to a stop codon within coding exon 11. This mutation has been identified in multiple individuals diagnosed with hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome (Heinimann K et al. Cancer. 1999 Jun;85(12):2512-8; Jasperson K et al. Fam. Cancer. 2010 Jun;9(2):99-107; Rossi BM et al. BMC Cancer. 2017 Sep 5;17(1):623). Tumor analysis performed on cancer samples from multiple individuals carrying this mutation showed consistent microsatellite instability and absence of MSH2 protein on immunohistochemistry (Leung S et al. Am. J. Pathol. 1998 Oct;153(4):1181-8; Casey G et al. JAMA. 2005 Feb;293(7):799-809; Mangold E et al. J. Pathol. 2005 Dec;207(4):385-95). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Invitae | RCV000552781 | SCV000625302 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2023-10-16 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu580*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MSH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 90763). For these reasons, this variant has been classified as Pathogenic. |
Myriad Genetics, |
RCV003452854 | SCV004187976 | pathogenic | Lynch syndrome 1 | 2023-08-03 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Mayo Clinic Laboratories, |
RCV000483706 | SCV000691906 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
German Consortium for Hereditary Breast and Ovarian Cancer, |
RCV000785573 | SCV000924145 | pathogenic | Neoplasm of ovary | 2018-12-01 | no assertion criteria provided | research | |
Constitutional Genetics Lab, |
RCV001249917 | SCV001423934 | pathogenic | Lynch-like syndrome | 2019-07-01 | no assertion criteria provided | clinical testing |